J Cancer 2020; 11(8):2273-2282. doi:10.7150/jca.38613 This issue

Research Paper

InvivoPen: A novel plasma source for in vivo cancer treatment

Xin Zhou1*, Dongyan Cai2,3*, Shaoqing Xiao1, Meng Ning4,5, Renwu Zhou7,8, Shuo Zhang6, Xiao Chen6, Kostya Ostrikov7,8, Xiaofeng Dai2,9*✉

1. Engineering Research Center of IoT Technology Applications (Ministry of Education), Department of Electronic Engineering, Jiangnan University, Wuxi, China
2. Wuxi School of Medicine, Jiangnan University, Wuxi, China
3. Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China
4. School of Mechanical Engineering, Jiangnan University ,Jiangsu Wuxi 214122, China
5. Laboratory of Advanced Food Manufacturing Technology of Jiangsu Province, Jiangnan University, Jiangsu Wuxi 214122, China
6. School of Biotechnology, Jiangnan University, Wuxi, China
7. School of Chemistry, Physics and Mechanical Engineering, Queensland University of Technology, Brisbane, Queensland 4059, Australia
8. Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland 4059, Australia
9. The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China
*These authors contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Zhou X, Cai D, Xiao S, Ning M, Zhou R, Zhang S, Chen X, Ostrikov K, Dai X. InvivoPen: A novel plasma source for in vivo cancer treatment. J Cancer 2020; 11(8):2273-2282. doi:10.7150/jca.38613. Available from https://www.jcancer.org/v11p2273.htm

File import instruction


Background: With the anti-cancer efficacies of cold atmospheric plasma being increasingly recognized in vitro, a demand on creating an effective tool feasible for in vivo animal treatment has emerged.

Methods: Through the use of co-axial needles with different calibers in diameter, we designed a novel in situ ejection source of cold atmospheric plasma, namely invivoPen, for animal experiments. It punches just a single pinhole that could considerably ease the complexity of operating with small animals such as mouse.

Results: We showed that invivoPen could deliver similar efficacies as plasma activated medium with reduced cost in suppressing cell proliferation and migration as well as potentially boosting the viabilities of mice receiving invivoPen treatment. Blood test, renal and liver functionalities tests all suggest that physical plasma could effectively return tumor-carrying mice to the healthy state without harm to body conditions, and invivoPen slightly outweighs PAM in boosting animal immunity and reducing inflammation.

Conclusion: Our study contributes to the community in providing a minimal invasive in situ plasma source, having partly explained the efficacies of cold atmospheric plasma in treating triple negative breast cancers, and proposing the potential synergies between physical plasma and conventional drugs for cancer treatment.

Keywords: triple negative breast cancer, plasma jet, invivoPen, plasma activated medium, cancer treatment